Detailed Narrative
Cenexi Reaches Critical EBITDA Breakeven
After several quarters of negative performance, Cenexi achieved EBITDA breakeven in Q1 FY26 with a profit of €0.9 million on revenue of €48 million. This turnaround was driven by improved gross margins (80% vs 78% YoY) and price increases negotiated last year. Management highlighted that the Fontenay site has improved order shipments and reduced downtime, while the Herouville-Saint-Clair site benefited from new product launches like Encepur. While Q2 will see a seasonal dip due to summer shutdowns, the long-term trajectory is aimed at high single-digit or low-teen EBITDA margins.
Aggressive GLP-1 and Cartridge Capacity Expansion
Gland is positioning itself as a major CDMO player in the GLP-1 space, currently operating a 40 million unit cartridge capacity. The company is adding another 100 million units of capacity, with the Factory Acceptance Test (FAT) scheduled for September and full commercial readiness by March/April 2026. Management expects to supply approximately 20 million units in FY27, primarily for the Liraglutide and Semaglutide markets. The new high-speed pen lines are capable of producing 160 to 200 pens per minute, offering significant throughput advantages over traditional vial filling.
US Market Dynamics and Pipeline Momentum
The US market contributed ₹7,443 million, representing 49% of total revenue. Growth was supported by the launch of 9 new molecules during the quarter, including Epinephrine and Acetaminophen bags. Despite a temporary slowdown in Enoxaparin supplies (₹70 crores this quarter vs ₹130-140 crores normally), management maintained its full-year guidance of mid-teen growth for the US. Key upcoming catalysts include the launch of Dalbavancin in the September quarter and the continued rollout of the RTU (Ready-To-Use) infusion bag portfolio, which now has 14 approved products out of 20 filed.
Geographic Diversification Beyond the US
Gland is successfully deepening its presence in non-US markets, with 'Other Regulated Markets' (Europe, Canada, Australia, NZ) growing 34% YoY to account for 27% of total revenue. The Rest of the World (RoW) segment saw a modest 5% increase to ₹2,978 million, but management believes this business can double over the next few years through portfolio optimization and activating dormant registrations. In India, the company is exploring inorganic opportunities to achieve significant growth, although it currently represents only 4% of total revenue.
R&D Strategy and Complex Injectables
R&D remains a core pillar, with ₹460 million spent in Q1 (4.4% of base revenue). The company filed one ANDA and received nine approvals during the quarter. The complex injectables pipeline is expanding, with six products already launched and three more awaiting approval. Gland's co-development model now comprises 15 products, including seven 505(b)(2) submissions. Management is also making a strategic push into advanced formats like dual and triple chamber bags and microsphere bulk filling to maintain its competitive edge in large-scale injectable solutions.